β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells
暂无分享,去创建一个
[1] C. Liedtke,et al. Genomic Profiling in Triple-Negative Breast Cancer , 2013, Breast Care.
[2] N. Harbeck,et al. Genomic Profiling in Luminal Breast Cancer , 2013, Breast Care.
[3] E. Kuipers,et al. β-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer , 2013, Oncogene.
[4] M. Dieci,et al. Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies , 2013, Drugs.
[5] C. Loddenkemper,et al. WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer , 2013, EMBO molecular medicine.
[6] K. Goss,et al. APC/β-catenin-rich complexes at membrane protrusions regulate mammary tumor cell migration and mesenchymal morphology , 2013, BMC Cancer.
[7] H. Joensuu,et al. Adjuvant treatments for triple-negative breast cancers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] G. von Minckwitz,et al. Neoadjuvant treatments for triple-negative breast cancer (TNBC). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] S. Weiss,et al. Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity , 2012, Proceedings of the National Academy of Sciences.
[10] Hans Clevers,et al. Wnt/β-Catenin Signaling and Disease , 2012, Cell.
[11] Yonghe Li,et al. The wnt/β‐catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer , 2012, Journal of cellular biochemistry.
[12] K. Goss,et al. Apc Mutation Enhances PyMT-Induced Mammary Tumorigenesis , 2011, PloS one.
[13] H. Sinn,et al. Triple-Negative Breast Cancer: Clinical and Histological Correlations , 2011, Breast Care.
[14] J. Reis-Filho,et al. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation , 2011, Modern Pathology.
[15] L. Carey,et al. Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.
[16] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[17] K. Goss,et al. A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer , 2010 .
[18] Michael Kahn,et al. Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells? , 2010, Clinical Cancer Research.
[19] W. Du,et al. Specific killing of Rb mutant cancer cells by inactivating TSC2. , 2010, Cancer cell.
[20] Louis Vermeulen,et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.
[21] O. Olopade,et al. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors , 2010, Breast Cancer Research and Treatment.
[22] Z. Szallasi,et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. O'toole,et al. Cytoplasmic Localization of β-Catenin is a Marker of Poor Outcome in Breast Cancer Patients , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[24] Charles M Perou,et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. , 2009, Cancer research.
[25] Edward J Oakeley,et al. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth , 2009, Breast Cancer Research.
[26] Debra L Winkeljohn. Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.
[27] M. Ringnér,et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.
[28] M. Leverkus. Faculty Opinions recommendation of Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. , 2008 .
[29] A. Fusco,et al. Roles of HMGA proteins in cancer , 2007, Nature Reviews Cancer.
[30] Daniel Birnbaum,et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.
[31] S. Weiss,et al. A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells , 2006, Nature Cell Biology.
[32] B. Porse,et al. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block , 2006, Nature Immunology.
[33] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[34] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[35] Karine Hovanes,et al. β-catenin–sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer , 2001, Nature Genetics.
[36] M. Hung,et al. β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .
[37] A. Sparks,et al. Identification of c-MYC as a target of the APC pathway. , 1998, Science.
[38] O. Olopade,et al. Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .
[39] K. Goss,et al. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. , 2010, Current drug targets.
[40] M. Hung,et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.